The global inhalable drugs market size was USD 33.31 billion in 2023, estimated at USD 35.44 billion in 2024 and is anticipated to reach around USD 65.51 billion by 2034, expanding at a CAGR of 6.34% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Inhalable Drugs Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Inhalable Drugs Market Revenue and Volume, by Drug Class, 2024-2034
8.1.1. Aerosol
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Dry powder formulation
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Spray
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Inhalable Drugs Market Revenue and Volume, by Application, 2024-2034
9.1.1. Respiratory diseases
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Non-respiratory disease
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Application (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Drug Class (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2034)
11.1. GlaxoSmithKline plc
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. AstraZeneca plc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Novartis International AG
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Boehringer Ingelheim
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Teva Pharmaceutical Industries Ltd.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Merck & Co., Inc.
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Pfizer Inc.
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Sanofi
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Cipla Ltd.
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. Vectura Group plc
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample